"New Agents Shake Up Treatment Landscape for Patients With HCC"
Josep Llovet, MD, PhD, founder and director of the Liver Cancer Program at the Icahn School of Medicine at Mount Sinai discusses the evolution of treatment options for patients with hepatocellular carcinoma. According to Dr. Llovet, Sorafenib has remained the standard of care and only treatment option for these patients prior to recent findings.
— Josep M. Llovet, MD, PhD, Director, Founder, The Liver Cancer Program, Professor, Medicine, Icahn School of Medicine at Mount Sinai